b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">30793108</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>25</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2531-1387</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>41</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <MedlineDate>2019 Jan-Mar</MedlineDate>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Hematology, transfusion and cell therapy</Title>\n                <ISOAbbreviation>Hematol Transfus Cell Ther</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>New proteasome inhibitors in the treatment of multiple myeloma.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>76-83</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S2531-1379(18)30124-X</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.htct.2018.07.003</ELocationID>\n            <Abstract>\n                <AbstractText>The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hungria</LastName>\n                    <ForeName>Vania Tietsche de Moraes</ForeName>\n                    <Initials>VTM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculdade de Ci\xc3\xaancias M\xc3\xa9dicas da Santa Casa de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, SP, Brazil. Electronic address: hungria@dialdata.com.br.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cruso\xc3\xa9</LastName>\n                    <ForeName>Edvan de Queiroz</ForeName>\n                    <Initials>EQ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universidade Federal da Bahia, Hospital Universit\xc3\xa1rio Professor Edgar Santos, Servi\xc3\xa7o de Hematologia, Salvador, BA, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bittencourt</LastName>\n                    <ForeName>Rosane Isabel</ForeName>\n                    <Initials>RI</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Cl\xc3\xadnicas de Porto Alegre, Servi\xc3\xa7o de Hematologia, Porto Alegre, RS, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Maiolino</LastName>\n                    <ForeName>Angelo</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Magalh\xc3\xa3es</LastName>\n                    <ForeName>Roberto Jos\xc3\xa9 Pessoa</ForeName>\n                    <Initials>RJP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sobrinho</LastName>\n                    <ForeName>Jairo do Nascimento</ForeName>\n                    <Initials>JDN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital Israelita Albert Einstein, S\xc3\xa3o Paulo, SP, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pinto</LastName>\n                    <ForeName>Jorge Vaz</ForeName>\n                    <Initials>JV</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universidade Cat\xc3\xb3lica de Bras\xc3\xadlia, Bras\xc3\xadlia, DF, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fortes</LastName>\n                    <ForeName>Ricardo Coutinho</ForeName>\n                    <Initials>RC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Evid\xc3\xaancias - Kantar Health, S\xc3\xa3o Paulo, SP, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Moreira</LastName>\n                    <ForeName>Eloisa de S\xc3\xa1</ForeName>\n                    <Initials>ES</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Evid\xc3\xaancias - Kantar Health, S\xc3\xa3o Paulo, SP, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tanaka</LastName>\n                    <ForeName>Paula Yurie</ForeName>\n                    <Initials>PY</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Takeda Pharma, S\xc3\xa3o Paulo, SP, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>15</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Brazil</Country>\n            <MedlineTA>Hematol Transfus Cell Ther</MedlineTA>\n            <NlmUniqueID>101725732</NlmUniqueID>\n            <ISSNLinking>2531-1379</ISSNLinking>\n        </MedlineJournalInfo>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Bortezomib</Keyword>\n            <Keyword MajorTopicYN="N">Carfilzomib</Keyword>\n            <Keyword MajorTopicYN="N">Ixazomib</Keyword>\n            <Keyword MajorTopicYN="N">Multiple myeloma</Keyword>\n            <Keyword MajorTopicYN="N">Proteasome inhibitors</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>07</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30793108</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.htct.2018.07.003</ArticleId>\n            <ArticleId IdType="pii">S2531-1379(18)30124-X</ArticleId>\n            <ArticleId IdType="pmc">PMC6371737</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Haematologica. 2008 May;93(5):791-2</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18450738</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2008 Aug 28;359(9):906-17</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18753647</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2010 Mar 1;70(5):1970-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20160034</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Pathol. 2010 Jun;176(6):2658-68</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20519734</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet. 2010 Dec 18;376(9758):2075-85</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21146205</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2012 Jan 1;18(1):15-20</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22019514</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2012 Jul 10;30(20):2475-82</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22585692</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2012 Aug 23;120(8):1589-96</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22791289</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2012 Oct 4;120(14):2817-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22833546</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Ther. 2013 Jun;12(6):831-43</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23729400</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2013 Sep 10;31(26):3279-87</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23897961</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Leuk Res. 2014 Jan;38(1):1-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24239172</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Cell Mol Med. 2014 Jun;18(6):947-61</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24712303</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Cancer Drug Targets. 2014;14(6):517-36</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25092212</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Card Fail. 2015 Feb;21(2):138-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25433360</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2015 Jan 8;372(2):142-52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25482145</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am Soc Clin Oncol Educ Book. 2015;:e504-11</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25993216</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Haematol. 2015 Dec;171(5):798-812</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26456076</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Immunol Res. 2015;2015:541984</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26636107</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2016 Jan;17(1):27-38</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26671818</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Leukemia. 2016 May;30(5):1005-17</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26710887</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mayo Clin Proc. 2016 Jan;91(1):101-19</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26763514</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood Cancer J. 2016 Jan 15;6:e384</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26771810</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Haematol. 2016 Jun;96(6):564-77</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26893241</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2016 Apr 28;374(17):1621-34</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27119237</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2016 Jun 30;127(26):3360-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27207788</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Hematol Oncol. 2016 Jun 30;9(1):52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27363832</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Leukemia. 2017 Jan;31(1):107-114</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27416912</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Haematol. 2016 Nov;97(5):416-429</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27528496</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Clin Oncol. 2017 Feb;14(2):100-113</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27531699</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Hematol. 2017 Jan;96(1):65-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27815724</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet. 2017 Feb 4;389(10068):519-527</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28017406</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CA Cancer J Clin. 2017 Jan;67(1):7-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28055103</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Clin Oncol. 2017 Jul;14(7):417-433</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28117417</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pharmaceuticals (Basel). 2017 Apr 11;10(2):</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28398261</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Drugs. 2017 Jul;28(6):660-668</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28430745</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Haematol. 2017 Oct;179(2):198-218</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28556890</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Semin Oncol Nurs. 2017 Aug;33(3):279-291</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28666621</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Hematol Oncol. 2017 Jul 6;10(1):137</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28683766</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ther Adv Hematol. 2017 Jul;8(7):209-220</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28694935</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Dis Primers. 2017 Jul 20;3:17046</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28726797</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Manag Res. 2017 Jul 10;9:287-298</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28744159</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2017 Sep 28;130(13):1507-1513</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28747306</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Haematologica. 2017 Oct;102(10):1767-1775</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28751562</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2017 Oct;18(10):1327-1337</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28843768</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Blood Med. 2017 Aug 22;8:107-121</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28860887</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 Jul 15;8(36):60656-60672</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28948001</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood Adv. 2017 Feb 27;1(7):449-454</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29296960</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'